drugset
drugset / Trial / NCT05810597

A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection Devices

NCT05810597 ↗

Phase 1 Completed 65 enrolled Eli Lilly and Company
RandomizedCrossoverOpen-labelBasic science

Summary

The main purpose of this study is to look at the amount of the study drug, tirzepatide, that gets into the blood stream and how long it takes the body to get rid of it when given using two different devices. The study will also evaluate the safety and tolerability of tirzepatide and information about any side effects experienced will be collected. For each participant, the total duration of the study will be approximately 14 weeks, including screening.

Timeline

Start
2023-04-03
Primary completion
2023-07-17
Completion
2023-07-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Tirzepatide Peptide 5 mg Subcutaneous

Indications

No indication recorded.